Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI France ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while iShares MSCI France ETF trades at $44.87. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | EWQ | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $48.35 |
52-Week Low | $20.06 | $41.43 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWQ trades at $46.07, up 0.33% today, with a bullish technical outlook from moving averages but neutral oscillators. Recent news highlights European equity strength and ECB rate hikes. Key support and resistance cluster at $46. A dividend of $1.09 is scheduled for June 2026.
Outlook is cautiously optimistic given technical momentum and European market tailwinds, but risks include geopolitical tensions and energy price volatility. The stock's performance is tied to broader European economic conditions and central bank policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
